We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized Study to Compare the Bioavailability of Three Mometasone Furoate 0.1% Topical Lotions

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00805155
First Posted: December 9, 2008
Last Update Posted: March 16, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Perrigo Company
  Purpose
The purpose of this study was to compare the relative vasoconstrictive effects of two test and one reference Mometasone Furoate 0.1% Topical Lotions in healthy, female subjects.

Condition Intervention
Healthy Drug: Mometasone Furoate 0.1% Topical Lotion-Reference Product Drug: Mometasone Furoate 0.1% Topical Lotion-Test product 1 Drug: Mometasone Furoate 0.1% Topical Lotion-Test Product 2

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Bioequivalence of Three Mometasone Furoate 0.1% Topical Lotions

Resource links provided by NLM:


Further study details as provided by Perrigo Company:

Primary Outcome Measures:
  • Vasoconstriction will be measured by the degree of skin blanching observed after treatment removal using a ChromaMeter [ Time Frame: Over the course of two days ]

Enrollment: 80
Study Start Date: February 2004
Study Completion Date: March 2004
Primary Completion Date: March 2004 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Cohort Group 1
Subjects number 1 to 20
Drug: Mometasone Furoate 0.1% Topical Lotion-Reference Product
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Drug: Mometasone Furoate 0.1% Topical Lotion-Test product 1
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Drug: Mometasone Furoate 0.1% Topical Lotion-Test Product 2
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Cohort Group 2
Subjects number 21 to 50
Drug: Mometasone Furoate 0.1% Topical Lotion-Reference Product
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Drug: Mometasone Furoate 0.1% Topical Lotion-Test product 1
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Drug: Mometasone Furoate 0.1% Topical Lotion-Test Product 2
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Cohort Group 3
Subject Numbers 51 to 80
Drug: Mometasone Furoate 0.1% Topical Lotion-Reference Product
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Drug: Mometasone Furoate 0.1% Topical Lotion-Test product 1
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Drug: Mometasone Furoate 0.1% Topical Lotion-Test Product 2
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy Community Volunteers
Criteria

Inclusion Criteria:

  • Non-tobacco using female subjects, 18 to 50 years of age
  • Demonstrated blanching response to Reference Drug
  • Body Mass Index (BMI) of 30 or less
  • Good health as determined by lack of clinically significant abnormalities in medical history and clinical assessment, as judged by the Investigator
  • Signed and dated informed consent form which meets all criteria of current FDA regulations

Exclusion Criteria:

  • History of allergy to systemic or topical corticosteroids
  • Presence of any skin condition or coloration that would interfere with the placement of test sites or the response or assessment of skin blanching
  • Presence of medical condition requiring regular treatment with prescription drugs
  • Drug or alcohol addiction requiring treatment in the past 12 months prior to dosing
  • Use of any tobacco products in the 30 days prior to study dosing
  • Use of any dermatological drug therapy on the flexor surface of the forearms within 30 days of dosing
  • Receipt of any drugs as part of a research study within 30 days prior to study dosing
  • Pregnant or lactating
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Perrigo Company
ClinicalTrials.gov Identifier: NCT00805155     History of Changes
Other Study ID Numbers: 10316908
First Submitted: December 5, 2008
First Posted: December 9, 2008
Last Update Posted: March 16, 2012
Last Verified: March 2012

Keywords provided by Perrigo Company:
Bioequivalence
Mometasone Furoate

Additional relevant MeSH terms:
Mometasone Furoate
Anti-Inflammatory Agents
Dermatologic Agents
Anti-Allergic Agents